Enhanced maternal and fetal PBPK models to predict drug exposures of novel oral and long-acting antivirals during pregnancy
08/09/2020 - 07/31/2022 (PI)The Regents of the University of Calif., U.C. San Diego National Institute o
LDR 01: LOC-IMPAACT Leadership Group: Mirochnick_YR08
01/01/2014 - 11/30/2021 (PI)Johns Hopkins University National Institute o
LDR09 - P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy...
07/01/2018 - 06/30/2021 (PI)Johns Hopkins University Gilead Sciences
IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2020 (PI)Johns Hopkins University Phivco UK II Ltd.
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)Univ of California, San Francisco NIH-NIAID
IMPAACT: HIV Treatment SC VC
06/01/2012 - 12/31/2014 (PI)Johns Hopkins University NIH-NIAID
IMPAACT: Network Executive Committee (NEC)
06/01/2012 - 12/31/2013 (PI)Johns Hopkins University NIH-NIAID
IMPAACT Group Leadership
07/01/2006 - 06/30/2013 (PI)Social & Scientific Systems Inc. NIH-NIAID
Pharmacokinetic Study of Praziquantel During Pregnancy
04/01/2009 - 03/31/2013 (PI)Rhode Island Hospital NIH-NIAID
IMPAACT Leadership: International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
06/01/2011 - 05/31/2012 (PI)Social & Scientific Systems Inc. NIH-NIAID
Showing 10 of 16 results.
Show All Results